Trial Profile
NCI-Sponsored Trial for the Evaluation of Safety and Preliminary Efficacy Using [F18] Fluorothymidine (FLT) As a Marker of Proliferation in Patients With Primary Brain Tumors
Status:
Completed
Phase of Trial:
Clinical Phase Unknown
Latest Information Update: 01 Mar 2019
Price :
$35
*
At a glance
- Drugs F-18 fluorothymidine (Primary)
- Indications Glioma
- Focus Diagnostic use
- 26 May 2014 New trial record